Concin N - Search Results

1

Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.

Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF Jr, Taschner PE, Hainaut P, Soussi T. Leroy B, et al. Among authors: concin n. Cancer Res. 2017 Mar 15;77(6):1250-1260. doi: 10.1158/0008-5472.CAN-16-2179. Cancer Res. 2017. PMID: 28254861 Free PMC article. Review.

2

Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer.

Tong D, Schneeberger C, Czerwenka K, Schmutzler RK, Speiser P, Kucera E, Concin N, Kubista E, Leodolter S, Zeillinger R. Tong D, et al. Among authors: concin n. Clin Cancer Res. 1999 Jun;5(6):1497-502. Clin Cancer Res. 1999. PMID: 10389938

3

P53 antibody response in patients with vulvar cancer.

Mayerhofer K, Hefler L, Schindl M, Concin N, Frischmuth K, Leodolter S, Zeillinger R, Reinthaller A, Kainz C. Mayerhofer K, et al. Among authors: concin n. Anticancer Res. 1999 May-Jun;19(3B):2323-6. Anticancer Res. 1999. PMID: 10472352

4

Association of in vitro invasiveness and gene expression of estrogen receptor, progesterone receptor, pS2 and plasminogen activator inhibitor-1 in human breast cancer cell lines.

Tong D, Czerwenka K, Sedlak J, Schneeberger C, Schiebel I, Concin N, Leodolter S, Zeillinger R. Tong D, et al. Among authors: concin n. Breast Cancer Res Treat. 1999 Jul;56(1):91-7. doi: 10.1023/a:1006262501062. Breast Cancer Res Treat. 1999. PMID: 10517346

5

p53-dependent radioresistance in ovarian carcinoma cell lines.

Concin N, Zeillinger C, Stimpfel M, Schiebel I, Tong D, Wolff U, Reiner A, Leodolter S, Zeillinger R. Concin N, et al. Cancer Lett. 2000 Mar 31;150(2):191-9. doi: 10.1016/s0304-3835(99)00393-6. Cancer Lett. 2000. PMID: 10704742

6

Role of p53 in G2/M cell cycle arrest and apoptosis in response to gamma-irradiation in ovarian carcinoma cell lines.

Concin N, Stimpfl M, Zeillinger C, Wolff U, Hefler L, Sedlak J, Leodolter S, Zeillinger R. Concin N, et al. Int J Oncol. 2003 Jan;22(1):51-7. Int J Oncol. 2003. PMID: 12469184

7

Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines.

Concin N, Zeillinger C, Tong D, Stimpfl M, König M, Printz D, Stonek F, Schneeberger C, Hefler L, Kainz C, Leodolter S, Haas OA, Zeillinger R. Concin N, et al. Breast Cancer Res Treat. 2003 May;79(1):37-46. doi: 10.1023/a:1023351717408. Breast Cancer Res Treat. 2003. PMID: 12779080

8

A polymorphism of the interleukin-1 receptor antagonist plays a prominent role within the interleukin-1 gene cluster in vulvar carcinogenesis.

Grimm C, Berger I, Tomovski C, Zeillinger R, Concin N, Leodolter S, Koelbl H, Tempfer CB, Hefler LA. Grimm C, et al. Among authors: concin n. Gynecol Oncol. 2004 Mar;92(3):936-40. doi: 10.1016/j.ygyno.2003.11.039. Gynecol Oncol. 2004. PMID: 14984963

9

Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo.

Concin N, Becker K, Slade N, Erster S, Mueller-Holzner E, Ulmer H, Daxenbichler G, Zeimet A, Zeillinger R, Marth C, Moll UM. Concin N, et al. Cancer Res. 2004 Apr 1;64(7):2449-60. doi: 10.1158/0008-5472.can-03-1060. Cancer Res. 2004. PMID: 15059898

10

Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.

Concin N, Hofstetter G, Berger A, Gehmacher A, Reimer D, Watrowski R, Tong D, Schuster E, Hefler L, Heim K, Mueller-Holzner E, Marth C, Moll UM, Zeimet AG, Zeillinger R. Concin N, et al. Clin Cancer Res. 2005 Dec 1;11(23):8372-83. doi: 10.1158/1078-0432.CCR-05-0899. Clin Cancer Res. 2005. PMID: 16322298

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

150 results

Search Page